Find clinical trials for Adenocarcinoma in Milano, Lombardia

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma

Cancer

Pancreatic Cancer

Stomach Cancer

Colorectal Cancer

Prostatic Cancer

Esophageal Cancer

Adenocarcinoma trials near Milano, Lombardia, ITA:

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...

Enrolling

Gastric Cancer, Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma

Drug: Ramucirumab

Drug: Paclitaxel

Phase 3

Daiichi Sankyo

Milano, Italy and 156 other locations

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for ...

Active, not recruiting

Pancreas Adenocarcinoma

Drug: Gemcitabine

Drug: nab paclitaxel

Phase 3

NovoCure

Alessandria, Italy and 197 other locations

Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) (daNIS-1)

The purpose of this Phase II study is to assess the efficacy and safety of NIS793 with and without spartalizumab in combination with gemcitabine/nab-...

Active, not recruiting

Metastatic Pancreatic Ductal Adenocarcinoma

Drug: nab-paclitaxel

Biological: NIS793

Phase 2

Novartis

Milano, MI, Italy and 30 other locations

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

and placebo in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).This study aims to explore whether blockade of Transforming Gr...

Active, not recruiting

Metastatic Pancreatic Ductal Adenocarcinoma

Drug: Gemcitabine

Drug: NIS793

Phase 3

Novartis

Milano, MI, Italy and 113 other locations

A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma (ILUSTRO)

The purpose of this study is to determine the Objective Response Rate (ORR) of zolbetuzimab as a single agent as assessed by an independent central r...

Enrolling

Pharmacokinetics of Oxaliplatin

Pharmacokinetics of Zolbetuximab

Drug: folinic acid

Drug: fluorouracil

Phase 2

Astellas

Milano, Italy and 25 other locations

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma...

Enrolling

Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma

Drug: Evorpacept (ALX148)

Drug: Trastuzumab

Phase 2, Phase 3

ALX Oncology

Milano, Italy and 54 other locations

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...

Enrolling

Advanced Upper Gastrointestinal Tract Adenocarcinoma

Drug: Capecitabine

Drug: Fluorouracil

Phase 3

Arcus Biosciences

Milano, Italy and 212 other locations

A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall surviv...

Active, not recruiting

Metastatic Pancreatic Adenocarcinoma

Metastatic Pancreatic Cancer

Drug: gemcitabine

Drug: nab-paclitaxel

Phase 2

Astellas

Milan, Italy and 137 other locations

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma...

Enrolling

Gastroesophageal Junction Cancer

Gastric Cancer

Drug: Apatinib

Drug: Ramucirumab+ paclitaxel

Phase 3

AstraZeneca

Milano, Italy and 118 other locations

A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas (SIRACUSA)

cancer in the pancreas.Adult participants with metastatic pancreatic adenocarcinoma will receive Test Product (TP) and Reference Product (RP...

Enrolling

Metastatic Pancreatic Adenocarcinoma

Drug: 5-Fluorouracil

Drug: Irinotecan liposome injection

Phase 1

Ipsen

Milano, Italy and 39 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Adenocarcinoma in .css-epvm6{white-space:nowrap;}Milano, Lombardia

Related conditions:

Adenocarcinoma trials near Milano, Lombardia, ITA:

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) (daNIS-1)

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas (SIRACUSA)

Find clinical trials for Adenocarcinoma in Milano, Lombardia